Focus: AVITA Medical is a biotechnology company specializing in autologous skin cell harvesting and treatment devices, primarily focused on dermatological applications including burns, wounds, and vitiligo. The company operates as a mid-cap biotech with commercial traction evidenced by recent revenue upgrades and cash-flow target resets.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
4 added, 3 removed. Backfill posture.
AVITA Medical is a commercially-maturing device biotech with strong near-term momentum but constrained hiring and narrow focus—suitable for specialists seeking deep domain expertise in regenerative dermatology, but risky for generalists seeking broad mobility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AVITA Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AVITA Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+2 more
AVITA Medical (OTCPK:AVHH.L) Stock Forecast & Analyst Predictions - Simply Wall Street
AVITA Medical (OTCPK:AVHH.L) Stock Forecast & Analyst Predictions Simply Wall Street
What AVITA Medical Holders Bought Into Before A 281% Run - Simply Wall Street
What AVITA Medical Holders Bought Into Before A 281% Run Simply Wall Street
Boardroom putsch looming at Genetic Signatures - NT News
Boardroom putsch looming at Genetic Signatures NT News
Why Is a Board Battle Brewing at Genetic Signatures? - Kalkine Media
Why Is a Board Battle Brewing at Genetic Signatures? Kalkine Media
Health Check: Board tussle looms at takeover target Genetic Signatures - Stockhead
Health Check: Board tussle looms at takeover target Genetic Signatures Stockhead
AVITA Medical (ASX:AVH) Shares Rise 4.06% as Commercial Momentum Builds - Kalkine
AVITA Medical (ASX:AVH) Shares Rise 4.06% as Commercial Momentum Builds Kalkine
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Parallel Mechanisms for Re-Epithelialization Following Skin Cell Suspension Autograft Application: Scientific Insights into Acute Wound Healing.
Autologous skin cell suspension plus phototherapy in stable vitiligo: findings from a US economic model.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo